Title
Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms
Date Issued
01 August 2018
Access level
open access
Resource Type
journal article
Author(s)
Méndez R.
Menéndez R.
Amara-Elori I.
Amaro R.
González P.
Posadas T.
Gimeno A.
España P.P.
Almirall J.
Torres A.
Centro de Investigación Biomédica
Publisher(s)
American Thoracic Society
Abstract
Rationale: Assessment of the inflammatory response can help the decision-making process when diagnosing community-acquired pneumonia (CAP), but there is a lack of information about the influence of time since onset of symptoms. Objectives: We studied the impact of the number of days since onset of symptoms on inflammatory cytokines and biomarker concentrations at CAP diagnosis in hospitalized patients. Methods: We performed a secondary analysis in two prospective cohorts including 541 patients in the derivation cohort and 422 in the validation cohort. The time since onset of symptoms was self-reported, and patients were classified as early presenters (,3 d) and nonearly presenters. Biomarkers (C-reactive protein [CRP] and procalcitonin [PCT] in both cohorts) and cytokines in the derivation cohort (IL-1, - 6, -8, -10, and tumor necrosis factor-a) were measured within 24 hours of hospital admission. Measurements and Main Results: In early presenters, CRP was significantly lower, whereas PCT, IL-6, and IL-8 were higher. Nonearly presenters showed significantly lower PCT, IL-6, and IL-8 levels. In the validation cohort, CRP and PCT exhibited identical patterns: CRP levels were 36.4% greater in patients with 3 or more days since onset of symptoms than in those with less than 3 days since symptom onset in the derivation cohort and 38.2% in the validation cohort. PCT levels were 40% lower in patients with 3 or more days since onset of symptoms in the derivation cohort and 56% in the validation cohort. Conclusions: Time since symptom onset modifies the systemic inflammatory profile at CAP diagnosis. This information has relevant clinical implications for management, and it should be taken into account in the design of future clinical trials.
Start page
370
End page
378
Volume
198
Issue
3
Language
English
OCDE Knowledge area
Sistema respiratorio
Subjects
Scopus EID
2-s2.0-85051114287
PubMed ID
Source
American Journal of Respiratory and Critical Care Medicine
ISSN of the container
1073449X
Sponsor(s)
Supported by the Fondo de Investigación Sanitaria grants 2003/0065 and 2008/0123; Sociedad Española de Neumología y Cirugía Torácica grants 2003/0065 and 145/2012; and Sociedad Valenciana de Neumología grant 2015. C.C. is the recipient of a European Respiratory Society Short Term Fellowship and Postdoctoral Grant, “Health Research and Innovation Strategic Plan (PERIS) 2016-2020”. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Sources of information:
Directorio de Producción Científica
Scopus